Erasca Securities Fraud Class Action
Erasca · Erasca securities and ERAS-0015 preclinical data
Investors allege that Erasca made false or misleading statements about preclinical data for ERAS-0015, including an allegedly improper comparison to Revolution Medicines data and potential patent-protection risks, causing losses to shareholders. The securities class action is ongoing, and the class has not yet been certified.
Case updates and reports
How to participate
Erasca Lead Plaintiff Application
Investors who purchased or acquired Erasca common stock between January 14, 2025, and April 26, 2026, and suffered losses may have sought appointment as lead plaintiff.
- Type
- Lead Plaintiff
- Lead plaintiff status
- Deadline passed
- Reported proof requirement
- Unclear
Faruqi & Faruqi investor inquiry
Investors who suffered losses in Erasca securities are encouraged to contact Faruqi & Faruqi regarding their options.
- Type
- Law Firm Signup
- Law firm signup
- Unknown
- Reported proof requirement
- Unclear
Erasca Investor Inquiry
The law firm invites Erasca investors to contact it regarding the securities class action, but specific eligibility criteria are not provided.
- Type
- Law Firm Signup
- Law firm signup
- Unknown
Erasca Stockholder Case Inquiry
Purchasers of Erasca common stock between January 14, 2025, and April 26, 2026, inclusive.
- Type
- Law Firm Signup
- Law firm signup
- Unknown
- Reported proof requirement
- Unclear
Bragar Eagel & Squire case inquiry
People who purchased or acquired Erasca common stock from January 14, 2025, through April 26, 2026, may contact Bragar Eagel & Squire regarding the action.
- Type
- Law Firm Signup
- Law firm signup
- Unknown
- Reported proof requirement
- Unclear
Erasca Investor Legal Consultation
The article invites investors who purchased Erasca shares between January 14, 2025 and April 26, 2026 and experienced an investment loss to contact the law firm regarding their legal rights.
- Type
- Law Firm Signup
- Law firm signup
- Unknown
- Reported proof requirement
- Unclear